A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Prader-Willi Syndrome Clinical Trial

Official title:

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05153434
• Other study ID #: AARD-203
• Status: Recruiting
• Phase: Phase 2
• Start date: May 27, 2022
• Est. completion date: March 1, 2024

Study information

• Verified date: September 2023
• Source: Aardvark Therapeutics, Inc.
• Contact: Andreas Niethammer, MD, PhD
• Phone: 858-349-4820
• Email: AndreasNiethammer[@]aardvarktherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome

Description:

This is a Phase 2, open-label study to investigate the effects of ARD-101 in subjects with Prader-Willi Syndrome. The study will consist of a Screening Period (up to 28 days), a Treatment Period (28 days), and a Follow-up Period (End-of-Study Visit within 14 days after receiving the last dose of ARD-101). The screening procedures will be initiated upon completion of the informed consent process. Following completion of screening procedures and confirmation of eligibility, subjects will be enrolled to receive ARD-101 in an outpatient setting and will be instructed to visit the clinical center periodically for safety and efficacy assessments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: March 1, 2024
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 17 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male and female subjects, 17-65 years of age
• Provide voluntary, written informed consent (parent(s) / legal guardian(s) of participant); provide voluntary, written assent (participants, as appropriate)
• PWS due to chromosome 15 micro-deletion, maternal uniparental disomy, or imprinting defect, confirmed by fluorescent in situ hybridization, chromosomal microarray, and/or methylation studies
• BMI = 18.5 kg/m²
• A HQ-CT score = 10
• If a subject has a diagnosis of type 2 diabetes, the following criteria must be met:

1. Hemoglobin A1c (HbA1c) <7.5% not being managed with insulin. Patients taking glucagon-like peptide (GLP)-1 analogues (exenatide or liraglutide) must have been on stable dose for greater than 3 months.

2. Fasting plasma glucose <140 mg/dL during the Screening Period

3. No history of ketoacidosis or hyperosmolar coma

• Stable or well-controlled blood pressure (BP) and vital signs. Specifically: Vital

signs after 5 minutes resting in seated position (feet flat on floor, back supported):

1. 95 mmHg <systolic blood pressure (SBP) <160 mmHg

2. 45 mmHg <diastolic blood pressure (DBP) <100 mmHg

3. 40 bpm <heart rate (HR) <100 bpm

• Stable body weight for ~2 months (self or guardian-reported loss/gain within ± 10%) prior to enrollment
• Standard 12-lead ECG parameters after 10 minutes resting in supine position in the following ranges; 120 ms <PR <220 ms, QRS <120 ms, QTc =430 ms if male, =450 ms if female and normal ECG tracing unless the Investigator considers an ECG abnormality to be not clinically relevant.
• Parent or guardian is able to communicate well with the investigator, to understand and comply with the requirements of the study, and be able to understand and sign the written informed consent. Assent is to be provided for the patient who cannot consent for himself or herself
• Results of screening clinical laboratory tests [complete blood count (CBC) with differential and platelets and chemistry profile] and vital signs must be within normal range or, if outside of the normal range, must be accepted by the investigator and sponsor as not clinically significant
• Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal lab range), do not require contraception during the study. This may also apply to subjects with documented hypogonadism with and without estrogen replacement therapy as per investigator judgement. All other females of child-bearing potential must agree to use contraception as outlined in the protocol
• Males with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study and for 90 days following the study.
• Patients previously treated with ARD-101 may be re-enrolled based on investigator decision and/if at least 3 months time has passed since the last dose.
• Patients must be on a stable dose of any allowed chronic concomitant medications while participating in the study, as described in protocol. This is defined as no changes in medication or dose for at least 30 days prior to Day 1 Stable concomitant usage (>3 months) of medications commonly used in PWS patients are allowed

Exclusion Criteria:

• Use of weight loss agents, including herbal medication, within 3 months prior to enrollment
• Diagnosis of schizophrenia, bipolar disorder, personality disorder, or other DSM-III disorders which the investigator believes will interfere significantly with study compliance
• A PHQ-9 score of =10
• Any suicidal ideation of type 4 or 5 on the C-SSRS
• Clinically significant illness in the 8 weeks prior to enrollment
• History of clinically significant bleeding disorders
• Current, clinically significant liver, renal, pulmonary, cardiac, oncologic, or gastrointestinal (GI) disease
• Diagnosis of type 1 diabetes mellitus or other active endocrine disorders (e.g., Cushing syndrome, or thyroid dysfunction except if on stable adequate thyroid or glucocorticoid replacement supplement)
• Liver disease or liver injury as indicated by abnormal liver function tests, SGOT (aspartate aminotransferase (AST)), alkaline phosphatase, or serum bilirubin (> 1.5 x upper limit of normal (ULN) for any of these tests) or history of hepatic cirrhosis
• History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine, blood urea nitrogen (BUN), or urinary constituents (e.g., albuminuria) or moderate to severe renal dysfunction as defined by the Cockroft Gault equation (< 50 mL/min)
• Significant history of abuse of drugs within 1 year prior to enrollment or a positive Drugs of Abuse (DOA) test at screening
• History of alcohol abuse within 1 year prior to enrollment or currently drinks in excess of 21 units per week (3 servings or units/day)
• Caffeine consumption exceeding 6 cups of caffeinated tea/coffee (or equivalent) per day
• Participation in any clinical study with an investigational drug/device within 1 month prior to enrollment
• Serious adverse reaction or significant hypersensitivity to any drug
• Clinically significant blood loss or blood donation > 500 mL within 3 months prior to enrollment
• Inadequate venous access
• History of significant drug hypersensitivity or anaphylaxis
• Any condition that the investigator or primary physician believes may not be appropriate for participating the study

Related Conditions & MeSH terms

• Prader-Willi Syndrome
• Syndrome

Intervention

Drug:
• ARD-101
Twice Daily, Oral Administration

Locations

Country	Name	City	State
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Stanford University	Palo Alto	California

Sponsors (3)

Lead Sponsor	Collaborator
Aardvark Therapeutics, Inc.	Children's Hospital Colorado, Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Effect on Anxiousness	Evaluation of patient's anxiousness via the PWS anxiousness and distress questionnaire (PADQ) obtained at study visits.	Baseline to Day 28
Other	The Change in Body Composition	The change in body composition based on evaluation of dual-energy X-ray absorptiometry (DEXA) scans at the end of treatment compared to baseline	Baseline to Day 28
Other	Effect on Psychiatric Status	Effect on psychiatric status through screening presence of suicidal ideation and behavior in addition to screening for degree of depression via the Columbia-Suicide Severity Rating Scale (C-SSRS), as assessed by caregiver.	Baseline to Day 28
Other	The Change in Body-Mass Index (BMI)	The change in body-mass index (BMI) at the end of treatment from the baseline as well as 28 days after end of treatment	Baseline to Day 28
Other	The Change in Waist Circumference	The change in waist circumference at the end of treatment from the baseline as well as 14 days after end of treatment	Baseline to Day 28
Other	Change in Patient Health	Difference from Day 28 to baseline in patient health as assessed by Patient Health Questionnaire ((PHQ)-9 Questionnaires)	Baseline to Day 28
Other	Change in Body Fat	Estimation of body fat by bioelectric impedance analysis at the end of treatment compared to baseline	Baseline to Day 28
Other	Change in GI Passage	Change in GI passage time to explore potentially reduced constipation	Baseline to Day 28
Other	Effect on Psychiatric Status	Effect on psychiatric status as assessed by Patient Health Questionnaire ((PHQ)-9 Questionnaires)	Baseline to Day 28
Primary	Incidence of Treatment-Emergent Adverse Events (TEAE)	The incidence of treatment-emergent adverse events (TEAE) during the treatment period	Baseline to Day 28
Secondary	Efficacy Evaluation of Hyperphagia in Prader-Willi Syndrome	Quantitative evaluation of hyperphagia via the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). Score will range from 0 (no hyperphagia behaviors) to 36 (most severe hyperphagia behaviors)	Baseline, Day 15, Day 28
Secondary	Effect on Weight	Quantitative effect on weight during the course of treatment	Baseline to Day 28